ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, N.
Right arrow Articles by McIntyre, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, N.
Right arrow Articles by McIntyre, N
Eur Respir J 1995; 8: 1384-1388
Copyright © ERS Journals Ltd 1995

Original Articles

Anti-tuberculosis medication and the liver: dangers and recommendations in management

NP Thompson, ME Caplin, MI Hamilton, SH Gillespie, SW Clarke, AK Burroughs, and N McIntyre

In the light of three deaths due to liver failure secondary to anti-tuberculosis therapy at the Royal Free Hospital, we have reviewed the current literature, and asked--How common is liver dysfunction with anti-tuberculosis medications and how might it be prevented? Anti-tuberculosis chemotherapy is associated with abnormalities in liver function tests in 10-25% of patients. Clinical hepatitis develops in about 3%, though estimates vary, and in these patients there is likely to be significant morbidity and mortality. On the basis of reported cases of tuberculosis, 160 patients in England and Wales can be expected to develop drug-induced hepatitis due to anti-tuberculosis therapy each year. There are published guidelines from the British and American Thoracic Societies regarding the choice of drug therapy for tuberculosis. Current recommendations with regard to monitoring liver function, and what to do when these tests become abnormal, vary considerably. We suggest a protocol for using liver function tests to monitor for liver damage, and give recommendations on what action to take when these become abnormal.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, and C. M. Tam
Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1391 - 1396.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. W. Rennie, G. H. Bothamley, D. Engova, and I. P. Bates
Patient choice promotes adherence in preventive treatment for latent tuberculosis
Eur. Respir. J., October 1, 2007; 30(4): 728 - 735.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Y. S. Kwon, W.-J. Koh, G. Y. Suh, M. P. Chung, H. Kim, and O. J. Kwon
Hepatitis C Virus Infection and Hepatotoxicity During Antituberculosis Chemotherapy
Chest, March 1, 2007; 131(3): 803 - 808.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. H. Lee, W.-J. Koh, M. S. Choi, G. Y. Suh, M. P. Chung, H. Kim, and O. J. Kwon
Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy
Chest, April 1, 2005; 127(4): 1304 - 1311.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the European Respiratory Society.